サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434552

抗肥満処方薬市場：薬剤クラス別、年齢層別、流通チャネル別-2024～2030年の世界予測

Anti-obesity Prescription Drugs Market by Drug Class (Bupropion & Naltrexone, Liraglutide, Lorcaserin), Age Group (Adult, Pediatric), Distribution Channel - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 189 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗肥満処方薬市場：薬剤クラス別、年齢層別、流通チャネル別-2024～2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 189 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗肥満処方薬市場規模は2023年に62億2,000万米ドルと推計され、2024年には67億1,000万米ドルに達し、CAGR 8.12%で2030年には107億4,000万米ドルに達すると予測されます。

抗肥満処方薬の世界市場

主な市場の統計
基準年[2023］ 62億2,000万米ドル
予測年[2024］ 67億1,000万米ドル
予測年 [2030] 107億4,000万米ドル
CAGR（%） 8.12%
抗肥満処方薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗肥満処方薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗肥満処方薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-抗肥満処方薬市場の市場規模および予測は？

2-抗肥満処方薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-抗肥満処方薬市場における技術動向と規制の枠組みは？

4-抗肥満処方薬市場における主要ベンダーの市場シェアは？

5-抗肥満処方薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 肥満および関連する慢性疾患の有病率の上昇
      • 不健康で座りっぱなしのライフスタイルの増加
      • 製薬企業、医科大学・医療機関、政府機関による医学調査の推進
    • 抑制要因
      • 抗肥満薬に関連した副作用
    • 機会
      • 新規抗肥満薬のイントロダクション
      • 肥満管理に対する意識の加速
    • 課題
      • 代替治療選択肢の利用可能性
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗肥満処方薬市場薬剤クラス別

  • ブプロピオンとナルトレキソン
  • リラグルチド
  • ロルカセリン
  • オルリファスト
  • フェンテルミン＆トピラメート

第7章 抗肥満処方薬市場：年齢層別

  • 成人用
  • 小児

第8章 抗肥満処方薬市場：流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 南北アメリカの抗肥満処方薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の抗肥満処方薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの抗肥満処方薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Alisier Drugs Pvt. Ltd.
    • Arena Pharmaceuticals Ltd
    • Arrowhead Pharmaceuticals, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Currax Pharmaceuticals LLC
    • Eisai Co., Ltd
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline PLC
    • Norgine BV
    • Novo Nordisk A/s
    • SHIONOGI & Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • VIVUS LLC
    • Zydus Lifesciences Limited
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTI-OBESITY PRESCRIPTION DRUGS MARKET DYNAMICS
  • FIGURE 7. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 10. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION & NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE & TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 146. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. ANTI-OBESITY PRESCRIPTION DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-4358BACA7FE8

[189 Pages Report] The Anti-obesity Prescription Drugs Market size was estimated at USD 6.22 billion in 2023 and expected to reach USD 6.71 billion in 2024, at a CAGR 8.12% to reach USD 10.74 billion by 2030.

Global Anti-obesity Prescription Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 6.22 billion
Estimated Year [2024] USD 6.71 billion
Forecast Year [2030] USD 10.74 billion
CAGR (%) 8.12%
Anti-obesity Prescription Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-obesity Prescription Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-obesity Prescription Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-obesity Prescription Drugs Market, highlighting leading vendors and their innovative profiles. These include Alisier Drugs Pvt. Ltd., Arena Pharmaceuticals Ltd, Arrowhead Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Norgine BV, Novo Nordisk A/s, SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, VIVUS LLC, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Anti-obesity Prescription Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Bupropion & Naltrexone
    • Liraglutide
    • Lorcaserin
    • Orlistat
    • Phentermine & Topiramate
  • Age Group
    • Adult
    • Pediatric
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anti-obesity Prescription Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-obesity Prescription Drugs Market?

3. What are the technology trends and regulatory frameworks in the Anti-obesity Prescription Drugs Market?

4. What is the market share of the leading vendors in the Anti-obesity Prescription Drugs Market?

5. Which modes and strategic moves are suitable for entering the Anti-obesity Prescription Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anti-obesity Prescription Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of obesity and related chronic diseases
      • 5.1.1.2. Growing unhealthy and sedentary lifestyle
      • 5.1.1.3. Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
    • 5.1.2. Restraints
      • 5.1.2.1. Side effect related to anti-obesity drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel anti-obesity drugs
      • 5.1.3.2. Accelerating awareness towards obesity management
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatment options
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anti-obesity Prescription Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Bupropion & Naltrexone
  • 6.3. Liraglutide
  • 6.4. Lorcaserin
  • 6.5. Orlistat
  • 6.6. Phentermine & Topiramate

7. Anti-obesity Prescription Drugs Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adult
  • 7.3. Pediatric

8. Anti-obesity Prescription Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Americas Anti-obesity Prescription Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anti-obesity Prescription Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Alisier Drugs Pvt. Ltd.
    • 13.1.2. Arena Pharmaceuticals Ltd
    • 13.1.3. Arrowhead Pharmaceuticals, Inc.
    • 13.1.4. Boehringer Ingelheim International GmbH
    • 13.1.5. Bristol-Myers Squibb Company
    • 13.1.6. Currax Pharmaceuticals LLC
    • 13.1.7. Eisai Co., Ltd
    • 13.1.8. F. Hoffmann-La Roche AG
    • 13.1.9. GlaxoSmithKline PLC
    • 13.1.10. Norgine BV
    • 13.1.11. Novo Nordisk A/s
    • 13.1.12. SHIONOGI & Co., Ltd.
    • 13.1.13. Takeda Pharmaceutical Company Limited
    • 13.1.14. VIVUS LLC
    • 13.1.15. Zydus Lifesciences Limited
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing